XOMA to Present at the H. C. Wainwright 20th Annual Global Investment Conference
August 28 2018 - 7:00AM
XOMA Corporation (NASDAQ: XOMA), a pioneer in the discovery,
development and licensing of therapeutic antibodies, announced
today its Chief Executive Officer, Jim Neal, will present at the H.
C. Wainwright 20th Annual Global Investment Conference on
Wednesday, September 5, 2018, at 11:40-12:05PM ET in New York, New
York.
About XOMA CorporationXOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotechnology and pharmaceutical companies.
The Company’s portfolio of partner-funded programs spans
multiple stages of the drug development process and across various
therapeutic areas. Many of these licenses are the result of
XOMA’s pioneering efforts in the discovery and development of
antibody therapeutics. The Company’s royalty-aggregator
business model includes acquiring additional licenses to
partner-funded programs. XOMA’s license portfolio has the
potential to generate significant milestone payments and royalty
revenue in the future. For more information, visit
www.xoma.com.
Forward-Looking StatementsCertain statements
contained in this press release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including
statements regarding the potential of XOMA’s portfolio of partnered
programs and licensed technologies generating substantial milestone
and royalty proceeds over time. These statements are based on
assumptions that may not prove accurate, and actual results could
differ materially from those anticipated due to certain risks
inherent in the biotechnology industry, including those related to
the fact that our product candidates subject to out-license
agreements are still being developed, and our licensees’ may
require substantial funds to continue development which may not be
available; we do not know whether there will be, or will continue
to be, a viable market for the products in which we have an
ownership or royalty interest; we may not be successful in entering
into out-license agreements for our product candidates; if our
therapeutic product candidates do not receive regulatory approval,
our third-party licensees will not be able to manufacture and
market them. Other potential risks to XOMA meeting these
expectations are described in more detail in XOMA's most recent
filing on Form 10-K and in other SEC filings. Consider such
risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date.
XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
Investor contact:Juliane
SnowdenOratorium Group, LLC+1
646-438-9754jsnowden@oratoriumgroup.com
Media contact:Kathy VincentKV
Consulting & Management+1
310-403-8951kathy@kathyvincent.com
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Sep 2023 to Sep 2024